Objective. To document changes in pulmonary arterial systolic pressure (PASP) in patients with SLE who have received CYC for any indication.
Introduction
Pulmonary arterial hypertension (PAH) can be a severe and devastating manifestation of CTDs like SSc, SLE and MCTD [1] . The reported prevalence in SLE varies from 0.5% to 43% [1] . The wide variation appears to be the result of using different diagnostic methods and definitions for PAH [2] . The pathophysiology of PAH in SLE is complex. Genetic and environmental factors cause chronic inflammation leading to an imbalance in pulmonary vasodilators and vasoconstrictors, endothelial proliferation and apoptosis, culminating in increased pulmonary vascular resistance [3] . Inflammatory infiltrates like macrophages and lymphocytes have been detected in plexiform lesions of the pulmonary vasculature, along with ANA, IgM RF and complement components similar to those observed in nephritis [2] . Overexpression of chemokines has been demonstrated in the pulmonary arteries of patients with severe PAH [3, 4] . These observations form the basis for immunosuppression in SLE with PAH. The efficacy of immunosuppressive therapy in SLE PAH has been addressed in case series, retrospective studies and one randomized controlled study [2, 5, 6] . It has been suggested that SLE PAH responds well to immunosuppression compared with PAH in other CTDs [2] . Most patients with SLE PAH also receive vasodilators similar to patients with idiopathic PAH and other CTDs. Other therapies recommended in SLE PAH include calcium channel blockers, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclins and anticoagulants. Survival in SLE PAH has been reported as 75% at 3 years, which is better than the survival in SSc PAH (47% at 3 years) [7] . On the basis of the previous literature, we aimed to document the change in PAH in SLE patients who have received CYC for any indication in a cohort from a tertiary referral rheumatology unit in South India.
Materials and methods
This is an observational study done between December 2011 and March 2014 carried out in the Department of Rheumatology at Nizam's Institute of Medical Sciences (NIMS), a tertiary care centre in South India. This observational study was conducted with prior approval from the NIMS institutional ethics committee (EC/NIMS/1346/2012) and patients gave informed consent to participate in the study. All adult patients fulfilling the 1997 revised criteria for classification of SLE with PAH were included in the study [8] . Screening transthoracic echocardiography (TTE) was done for all the patients with clinical suspicion of heart disease. Repeat TTE was done to confirm the diagnosis of PAH by a single experienced cardiologist who was blinded to the treatment details. PAH was defined as a pulmonary arterial systolic pressure (PASP) of >30 mmHg at rest as measured by TTE. PAH was classified as mild (PASP 30<45 mmHg), moderate (PASP 4559 mmHg) or severe (PASP >60 mmHg) [9] . Clinical examination, chest radiographs and, when indicated, high-resolution CT (HRCT) of the chest and a pulmonary angiogram were done to rule out lung parenchymal or thromboembolic disease based on the opinion of the treating physicians. The clinical stage of PAH [New York Heart Association (NYHA) class] was assessed by the rheumatologists, who were not blinded to the treatment. Patients with overlap syndromes, aPL syndrome, left heart disease, valvular heart disease, congenital heart disease, HIV and portal hypertension were excluded. All patients received six pulses of i.v. CYC 5001000 mg/m 2 monthly (n = 23) or fortnightly (n = 1) with oral steroids 0.51 mg/kg for 4 weeks (and slowly tapered thereafter 
Results

Baseline parameters
Twenty-four female patients were studied. Baseline demographic characteristics are presented in Table 1 . RP was seen in three patients. The clinical and haemodynamic characteristics (PASP) of the entire cohort are summarized in Table 2 .
Response to therapy with immunosuppression and/or vasodilators All patients received i.v. CYC (monthly, n = 23; fortnightly, n = 1). Sildenafil or tadalafil at the maximum tolerated doses were given in all except in four patients (three had mild PAH and the reason was unknown in one patient with moderate PAH). Most of the patients at the end of 6 months were on low-dose oral prednisolone (<7.5 mg/day).
PASP
In the 24 patients studied, PASP decreased from the baseline in 21 patients. In 11 (45.83%) patients there was a decrease in PASP of >15 mmHg with an improvement in functional class (responders). In three patients it worsened. There was a decrease in mean PASP from 59.33 mmHg (S.D. 18.68) at baseline to 43.29 mmHg (S.D. 20.91) at the end of 6 months (P < 0.0001). In four patients who received only immunosuppression, the mean PASP decreased from 39.75 mmHg (S.D. 6.95) at baseline to 34.25 mmHg (S.D. 8.3) at the end of 6 months (P = 0.04). Even in patients asymptomatic for PAH, there was a decrease in mean PASP from 46.4 to 34 mmHg (P = 0.15) ( Table 3) .
NYHA functional class
Improvement in NYHA functional class was noted in 22 patients. The change in functional class for NYHA classes III and IV is depicted in Table 4 . Of the six patients in NYHA class II, one worsened to NYHA class III, one maintained the same class, three improved to NYHA class I and one was asymptomatic. None of the patients in class I progressed.
Six minute walk test
The mean 6 min walk distance improved from 312.04 to 420.16 m at the end of 6 months (data available for six patients).
Deaths
Two deaths occurred during the median follow-up period of 12 months (range 653). One was due to PAH and the other was due to septic shock. In both, baseline PASP was 90 mmHg and both remained non-responders.
Discussion
This study documented the change in PASP in 24 patients with SLE PAH who received CYC for any reason. Twenty patients also received vasodilators. In this study of 24 patients, 7 had mild PAH (PASP 3045 mmHg). Of these seven, three were asymptomatic. There was a mean 18.15 mmHg (27.03%) decline in PASP in the 24 patients who received immunosuppression and vasodilator therapy. All of the symptomatic PAH patients reported improvement in NYHA functional class except two (one remained in the same NYHA class II and one progressed from NYHA class II to III). The mean decline in PASP of 18.15 mmHg (27.03%) in our cohort is higher than the expected change in PASP of 211 mmHg due to vasodilators alone as studied in patients with idiopathic PAH [10] . It is possible that immunosuppression might have added to the effect of the vasodilators. In 2008 Jais et al. [2] suggested that in their group of 23 patients with SLE/MCTD PAH with a mean pulmonary arterial pressure (mPAP) of 58 mmHg (S.D. 6), immunosuppression alone was effective in 50%. Since current consensus is to use vasodilators in PAH of any cause [11] , and we could not use immunosuppressive therapy alone in our patients, we used vasodilators for our patients.
No difference was identified in baseline parameters such as age, duration of PAH, right ventricular systolic pressure (RVSP), NYHA functional class and disease activity (SLEDAI) between responders and non-responders in our study (Table 5 ). Although not statistically significant, responders had a longer duration of SLE. Jais et al. [2] noted that responders had significantly lower NYHA functional class and less severe haemodynamic values at baseline. There was a trend towards more dsDNA, antiSm antibody positivity and SLE activity (as measured by the SLEDAI) in responders in this study, although the Pvalue was not significant. Two of 13 (15.39%) nonresponder patients died in our study at 12 and 18 months after the diagnosis of PAH. Both had severe PAH. Of 11 patients with severe PAH, 7 responded.
In this study, TTE was used to make the diagnosis of PAH. It is the most widely available non-invasive tool for assessment of PAH. It provides several variables that correlate with right heart haemodynamics, including PASP. The estimation of PASP is based on the peak velocity of the jet of tricuspid regurgitation. PASP measured by TTE correlates well with that measured by right heart catheterization (r = 0.89) [9] . Doppler echocardiography has a sensitivity of 0.791.00 for estimating PAP. The specificity of Doppler echocardiography in estimating PAH is 0.680.98 [12] . Two-dimensional (2D) echocardiography is inaccurate as a screening tool for mild asymptomatic PAH [13] . While it may be argued that TTE is not an accurate method of estimating PASP, the improvement in NYHA functional class argues for the efficacy of the therapy given to these patients.
Seventy-three cases of SLE PAH have been reported in the literature [2, 5, 1416 ] who have received immunosuppression in the form of steroids (n = 73), CYC (n = 51), ciclosporin (n = 2) and rituximab (n = 1), along with vasodilators (n = 21). Among 73 patients, 53 (73%) were responders. However, the definition of PAH and responders varied among these studies. Responders were variably defined as patients with haemodynamic improvement defined as mPAP <40 mmHg and/or normal cardiac index [2] , mPAP <25 mmHg or a >10% reduction from baseline [15] , a decrease in PASP 520% or <30 mmHg [6] , along with patients in NYHA class I or II [2, 14] . Responders were those with less severe PAH in terms of NYHA functional class and haemodynamic values such as mPAP, cardiac index and pulmonary vascular resistance [2, 14] . Our study defined responders more stringently, i.e a decrease in PASP 515 mmHg considering inter and intraobserver variations. This might be the reason for the lower response rate (45.83%) in our study. Table 6 summarizes several studies that have tried immunosuppression in SLE PAH. Except in the study by Gonzalez-Lopez et al. [6] , right heart catheterization was used in all the studies as a diagnostic modality. GonzalezLopez et al. [6] studied 34 SLE patients with mild and moderate PASP (>30 mmHg) as defined by 2D echocardiography and randomized them to receive i.v. CYC or oral enalapril for 6 months. The primary outcome, which was a statistically significant reduction of PASP from baseline to 6 months, was achieved in both arms [13 mmHg in the CYC group (P < 0.001); 8 mmHg in the enalapril group (P = 0.02)]. When subanalysis was carried out in patients with a PASP >35 mmHg, only i.v. CYC was effective. The NYHA functional class also improved only in the i.v. CYC group. Severe PAH patients were not included in this study.
Jais et al. [2] carried out a retrospective analysis of 23 SLE and MCTD patients with PAH. Of the 13 SLE PAH patients, 9 received i.v. CYC and steroids but no vasodilators. Of these nine, four responded. The responders group had significantly lower NYHA functional class and less 1 and SS, 4) . All patients received intense immunosuppression therapy with i.v. CYC (500 mg 10 times in 1 year; once a month for the first 3 months followed by once every 13 months), glucocorticosteroids 1 mg/kg and vasodilators (prostacyclins, 11; phosphodiesterase, 5; inhibitors, 6; bosentan, 5). They were compared with historical controls. Haemodynamic responders were those with an mPAP reduction <25 mmHg or a >10% reduction from the baseline value. Six of the seven SLE PAH patients were classified as responders in this study. The authors noted that the intense immunosuppression therapy was instituted very late in the SLE PAH patient who had not responded.
NR NR NR NR R NR R NR R NR R NR R R NR R R NR NR R NR R R NR
We had five asymptomatic patients in our cohort. Kamel et al. [17] noted 8 asymptomatic PAH cases (PASP range 3461.2 mmHg) out of 74 cases by TTE screening over a period of 1 year. Humbert et al. [18] noted 16 incident PAH cases in a scleroderma screening programme over a period of 2 years. These patients had lower NYHA functional class, lower pulmonary haemodynamic values and better survival rates when compared with patients in the routine practice cohort. Considering the fact that early detection and therapeutic intervention in scleroderma PAH improves long-term outcomes, we propose screening for PAH in SLE [19] .
A very high association of SLE PAH with aCLs has been reported in two studies (87.5% and 56%; [20] and [6] , respectively). However, only 2 of 23 patients tested in our study were positive (as measured by ELISA and defined with a cut-off of >40 IgG phospholipid units or >40 IgM phospholipid units).
Limitations
This is a single-centre study with a small sample size. PAPs were not measured by right heart catheterization, which is the gold standard. Due to cost constraints, TTE was used for baseline and follow-up evaluation of PASP at 6 months. There is no group with vasodilators alone to compare with the immunosuppression group; if carried out, this may reveal further the importance of immunosuppression.
Conclusion
Immunosuppression and vasodilators produced significant improvement in SLE PAH over 6 months. Immunosuppression may add to the effect of vasodilators in SLE PAH. Further studies that use catheter-based assessment of the change in PASP with treatment and randomize SLE patients to immunosuppression with vasodilators and vasodilators alone will improve our understanding of optimal therapy in this group.
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